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Aim To determine whether serum ferritin, liver transami-
nases, and regularity and type of iron chelation protocol 
can be used to predict liver iron load as assessed by T2* 
magnetic resonance imaging (MRI) in patients with beta 
thalassemia major (TM).
Methods This cross-sectional study, conducted from 
March 1, 2014 to March 1, 2015, involved 90 patients with 
beta TM on regular packed red blood cell transfusion. Liver 
and cardiac iron load were evaluated with T2* MRI. Compli-
ance with iron-chelating agents, deferoxamine or defera-
sirox, and regularity of their use, as well as serum ferritin 
and liver transaminase levels were assessed.
Results Patients with high serum ferritin were 2.068 times 
(95% confidence interval 1.26-3.37) more likely to have 
higher liver or cardiac iron load. High serum aspartate ami-
notransferases and irregular use of iron chelating agents, 
but not their type, predicted higher cardiac iron load. In a 
multiple regression model, serum ferritin level was the only 
significant predictor of liver and myocardial iron load.
Conclusions Higher serum ferritin strongly predicted the 
severity of cardiac and liver iron load. Irregular use of chela-
tor drugs was associated with a higher risk of cardiac and 
liver iron load, regardless of the type of chelating agent.
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Excess iron load, resulting from increased gastrointestinal 
absorption and repeated red blood cell transfusions, in pa-
tients with thalassemia heralds a wide range of complica-
tions, including arrhythmia and congestive heart failure (1). 
Almost 50% of patients with beta-thalassemia major (TM), 
a transfusion-dependent form of thalassemia syndromes, 
are affected by myocardial siderosis before the age of 35 
and are at risk of congestive heart failure (2) as a major 
cause of morbidity (3). Also, it is important to point out 
that in patients with beta TM, transfusion-dependent com-
plications comprise the highest share of economic (4) and 
global burden (5).
Two main predictors of survival in TM patients are iron 
load in organs and adherence to chelating drugs (6). In-
deed, persistent serum ferritin above 2500 ng/mL and 
liver iron concentration (LIC) above 15 mg/g dry weight 
can significantly predict 10-year survival of patients with 
TM (7). Currently there are three available iron-chelating 
drugs: deferoxamine (DFO) as the first available agent, 
deferiprone (DFP), and deferasirox (DFX) (6), which are 
shown to be equally effective in preventing complica-
tions (8,9).
Magnetic resonance imaging (MRI) is a non-invasive and 
rapid method of measurement of tissue iron in the cardiac 
muscle and liver. Its results are presented in terms of R2, 
R2*, T2, and T2* (10). The T2 star (T2*) is inherently similar 
to T2 signal in MRI, yet it gives a more realistic estimate of 
signal decoy due to intrinsic tissue properties, such as ex-
cess iron load (11). T2* value of less than 20 ms is a strong 
predictor of higher risks for arrhythmia and/or congestive 
heart failure (CHF) (12). Liver and cardiac iron load assessed 
by MRI T2*, together with iron chelating therapy, can be 
used as valuable indicators of transfusion-dependent side 
effects, as certified by the notable decrease in the overall 
mortality rate of beta-TM patients after the emergence of 
cardiac T2* MRI in 1999 (13).
Despite reliable results obtained by T2*MRI (14), especial-
ly for myocardial iron load in predicting heart failure (15), 
there are debates about the relevance of liver and cardi-
ac iron concentrations for the overall prognosis. Current 
guidelines recommend the liver and cardiac T2*MRI to be 
performed annually in all patients older than 6 years with 
ferritin above 1000 ng/mL, relying on the fact that serum 
ferritin is the marker of choice to monitor total body iron 
storages (16). A part of the inter-individual heterogene-
ity in total body iron load is predicted by iron chelation 
protocol (17-19).
Pursuing the idea that serum markers can be used as a 
proxy to total body and liver iron load, we aimed to de-
velop a model to predict cardiac and liver iron load using 
ferritin, liver transaminases, and regularity and type of iron 
chelation protocol. We hypothesize that liver transaminas-
es, serum ferritin, and dosage of iron chelating treatment 
can add to the predictive value of iron load in T2*MRI.
The aims of the current study were to assess: 1) whether 
serum ferritin level can independently predict hepatic or 
cardiac iron load, 2) whether the dosage or type of iron 
chelating agent is able to estimate the degree of hepatic or 
cardiac iron load, 3) whether the severity of hepatic or car-
diac iron load can be predicted by serum AST or ALT.
MAteRiAl And MethodS
Study design
This single-center cross-sectional study was conducted 
from March 1, 2014 to March 1, 2015 in the Thalassemia 
Clinic of Children’s Medical Center, Pediatric Center of Ex-
cellence in Tehran, Iran.
The sample size was calculated based on the formula for 
cross-sectional studies (20):
Adopting 0.05 as the significance level (Zα/2 = 1.96), stan-
dard deviation from the study by Majd et al (21), and d 
of 10 ng/dL for ferritin and 2 milliseconds for cardiac iron 
load, we calculated that the sample size for the estimation 
of serum ferritin levels should be 100 and for myocardial 
and liver iron load estimation it should be 88.
Participants’ demographic data
Out of 154 patients with beta-TM treated at the Thalas-
semia Clinic, 138 accepted to participate in the study. The 
diagnosis of beta-TM was based on patient’s clinical histo-
ry, complete blood count, and hemoglobin electrophore-
sis performed at the Children’s Medical Center laboratory. 
Medical records of all patients were reviewed. In patients 
who did not have serum viral markers obtained in the pe-
riod of at most three months before the study, viral marker 
examination was requested. Three patients were excluded 
due to co-morbid hepatitis C infection. Ten more patients 
were excluded due to abnormal liver ultrasonography and 
35 patients due to missing results from T2* MRI. Finally, the 
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study recruited 90 patients (51 or 56.7% female) with be-
ta-TM and regular packed red blood cell (RBC) transfusion 
and a mean age of 20.5 ± 7.6 years (range 7-25).
transfusion history, type, and dosage of iron-chelating 
agents
All patients had received at least 8 regular packed RBC 
transfusions per year for the preceding 3 years. Transfusion 
duration was calculated from the date of the first registra-
tion at the clinic and imaging/sampling date. At the time 
of the sampling, all patients were receiving iron chelators, 
including DFO, DFX, or both.
Iron chelation therapy in all patients had been started 
with DFO after at least 10 transfusions or after serum fer-
ritin increased to above 1000 μg/L, whichever came first 
(22). Treatment was started at 20 mg/kg administered in 
an 8-hour transfusion 5 times a week in children under the 
age of 16, with the goal to maintain serum ferritin below 
2000 μg/L, or better below 1000 μg/L, without increasing 
the dose over 40 mg/kg (22). For children under the age of 
2 years, DFX was started as first-line therapy with 10 mg/
kg/day tablets, and titrated to obtain serum ferritin below 
1000 μg/L. DFO and DFX dose were titrated based on se-
rum ferritin levels obtained three-monthly and annual liver 
and heart T2* MRI. No patient had been registered after 16 
years of age.
Compliance with DFO was calculated as the percentage 
of completed infusions by the MP Thalapump 20 (Micrel 
Medical Devices, Athens, Greece) specified for each pa-
tient, as described before (23). Compliance with DFX was 
assessed with a self-report questionnaire, either filled out 
by the patient or a caregiver/parent if the patient was 
not cognitively competent. Adequate dosing of DFO was 
defined as a daily dose of 20-40 mg/kg for children and 
50-60 mg/kg for adults (22), subcutaneously injected 5-6 
times a week, started before the age of six years. Ade-
quate dosing of DFX was defined as a daily oral intake of 
20-40 mg/kg of dispersible tablets, started before the age 
of six years (24). The cut-off levels for regular iron chela-
tors adherence were adopted from the study by Cohen et 
al (25). Patients were, therefore, categorized as “irregular 
users” if in three months of average follow-up they had 
received less than 50 mg/kg/day (20 mg/kg/day in chil-
dren) of DFO or less than 30 mg/kg/day of DFX. Impor-
tantly, no change in type or dosage of medications had 
occurred in the 6 months preceding the date of imaging 
in any of the patients.
t2* magnetic resonance imaging (MRi)
All Thalassemia Clinic patients undergo annual examina-
tion for cardiac and liver iron load by liver and heart T2* 
MRI (Siemens, Avanto, 1.5 Tesla, Munich, Germany) at the 
Pardis Noor referral center of Iranian Red Crescent Organi-
zation in Tehran. The imaging was scheduled for at least 5 
days of the last transfusion.
Similar to the T2 signal in MRI, the T2* signal measures the 
time constant of magnetization decoy, ie, relaxation time. 
Due to its paramagnetic properties, excess iron accumula-
tion in the tissue shortens the relaxation time, hence ac-
celerating the decrease in signal intensity (26). Suscepti-
bility-induced distortions in the magnetic field result in a 
faster signal decoy compared to the true relaxation time 
(T2) predicted for the tissue. T2* hence measures the ef-
fective “observed” T2, yielding a lower value compared 
with the predicted T2 (11). T2* has been shown in patients 
with mild to moderate iron overload to be a reliable in-
dicator of LIC (26,27) and cardiac iron load (28). T2* less 
than 20 ms indicates a high LIC, while T2* of less than 10 
ms indicates a severely high LIC. Compared with LIC, T2* 
generally less accurately estimates cardiac iron concentra-
tion (22).
The severity of iron overload in the heart and liver was de-
termined from the patients’ most recent T2* liver and heart 
MR images. According to the manufacturer’s guideline, liv-
er iron load was considered normal if hepatic T2* values 
were above 6.3 ms, mild if they ranged from 2.8-6.3 ms, 
moderate if they ranged from 1.4-2.7 ms, and severe if they 
were below 1.4 ms. Also, a T2* signal above 20 ms indi-
cated normal cardiac iron load, a signal from 14-20 ms in-
dicated mild iron load, a signal from 10-14 ms indicated 
moderate iron load, while a signal lower than 10 ms indi-
cated severe iron.
Serum measurements, echocardiography, and liver 
ultrasonography
Serum aspartate aminotransferase (AST), alanine amin-
otransferase (ALT), and serum ferritin levels were measured 
at the time of MRI imaging.
Since fatty liver and liver heterogeneity are common con-
founding factors in the measurement of liver iron load, 
patients were also scheduled for abdominal ultrasonog-
raphy (GE VIVID 3, GE Medical Systems, Chicago, IL, USA, 
probe 3 MHz) by an expert radiologist, to assess 
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whether they have co-existing fatty liver or active hepatitis. 
All patients also underwent echocardiography (GE VIVID 3, 
probe 3 MHz). Hence, ten patients were excluded due to 
abnormal liver ultrasonography findings.
Importantly, laboratory and imaging procedures were 
performed at no expense for the patients. Before be-
ing asked to sign informed consent forms, patients or 
their legal guardians were informed about the aims of 
the study and assured that their anonymity would be re-
spected. The study was approved by the review board of 
Children’s Medical Center and Iranian Red Crescent Or-
ganization.
Statistical analysis
The Kolmogorov-Smirnov test was used to assess the 
normality of distribution of age, sex, serum AST, serum 
ALT, and ferritin levels. To assess if AST, ALT, ferritin, regu-
larity of iron chelator use, and age were significantly as-
sociated with the stages of liver and cardiac iron load we 
used the χ2 test or Fisher exact test, where applicable, and 
calculated the odds ratios (OR). Age was entered into the 
non-parametric comparison with use of Mann-Whitney 
U tests with previous dichotomous variables. Finally, the 
variables that were significant in previous analyses were 
entered into a multiple linear regression analysis to as-
sess if they predicted liver or cardiac iron load indepen-
dently of other variables. We tested multivariate normal-
ity through normal Q-Q plots for each significant variable. 
We entered the variables in a step-wise manner, mean-
ing that the next variable was entered if the probability 
of F remained significant at 0.05 levels. Collinearity was 
assessed with use of Durbin-Watson test and homosce-
dasticity of all significant and non-significant variables 
by post-hoc plotting of square residues against predicted 
values. The level of significance was set at less than 0.05. 
Statistical analyses were performed with SPSS, version 23 
(IBM, Armonk, NY, USA).
ReSultS
The study involved 90 patients (51 or 56.7% female), with 
the mean age of 20.5 ± 7.6 years. Most patients were old-
er than 20 years (n = 54, 60%), 32 patients were between 
10-20 years old, and only 4 patients were younger than 
10 years. Most patients (n = 84, 93.3%) received RBC 
transfusion for 5-20 years, one patient for more than 
20 years, and 5 patients (5.6%) for less than 5 years. 
Fifty-two patients received DFO (Desferal, Novartis, 
Basel, Switzerland) (57.7%), 29 patients DFX (Exjade, No-
vartis) (32.2%), and 9 patients (10%) received both. Most 
patients used iron chelators regularly (n = 61, 67.8%). The 
cut-off for liver aminotransferases was 40 IU/L (in patients 
older than 14 years and age-specific cut-off for patients 
younger than 14 years). According to this cut-off, 79.9% 
and 86.7% of patients had AST and ALT levels within 
the reference range, respectively. According to the fer-
ritin cut-off of less than 2000 ng/mL, the patients were 
categorized to “normal/low” or “abnormal/high” ferritin 
groups (Table 1). Based on the cut-off values described 
in the methods section, 36 (40%) patients had mild liver 
iron load, 27 (30%) patients had moderate iron load, and 
4 (4.4%) patients had severe iron load (Table 1). Most pa-
tients had normal (n = 55, 61%) or mild (n = 20, 22.2%) car-
diac iron load (Table 1).
There was no difference in liver or heart iron load between 
male and female patients (Table 2). Also, the cross-tabula-
tion of age groups with different grades of liver and heart 
iron load revealed no significant results (Table 2). Signifi-
cantly more men (46.1% vs 25.5%) than women had mod-
erate to high liver iron load (P = 0.032, chi square test). 
Hence, women were 1.53 times less likely to have moder-
tAble 1. the proportion of patients with normal/abnormal 
aspartate aminotransferase, alanine aminotransferase, and fer-
ritin levels and in each group based on t2*magnetic resonance 
imaging of liver and heart iron load
Parameter no. (%) of patients
Serum aspartate aminotransferase (iu/dl)
low to normal 71 (78.9)
high/abnormal 19 (21.1)
Serum alanine aminotransferase (iu/dl)
low to normal 78 (86.7)
high/abnormal 12 (13.3)
Serum ferritin (ng/dl)










moderate  7 (7.8)
severe  8 (8.9)
*liver and myocardial iron load are based on t2*MRi values expressed 
in milliseconds.
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ate to high liver iron load (odds ratio [OR] 1.53, 95% confi-
dence interval [CI] 1.08-2.42, P = 0.041). No sex difference in 
cardiac iron load was observed.
We compared the rates of high AST, ALT, and ferritin levels 
in different stages of liver and cardiac iron load with χ2 test. 
Neither high serum ALT nor AST were associated with liver 
iron load (P = 0.48 and 0.107, respectively) (Table 2). High 
AST but not ALT was associated with severe cardiac iron 
load (P = 0.03), as patients with high AST were 1.37 times 
more likely to have moderate to severe cardiac iron load 
(OR 1.38, 95% CI 1.013-2.11, P = 0.015).
High serum ferritin levels were associated with higher liv-
er and cardiac iron load (P = 0.001 and 0.001, respectively) 
(Table 2). Patients with high serum ferritin were 2.068 times 
more likely to have high liver iron load (OR 2.068, 95%, 95% 
CI 1.26-3.37, P = 0.001). They were also 1.87 times more like-
ly to have high cardiac iron load (OR 1.87, 95% CI 1.38-2.54, 
P = 0.001).
Patients with self-reported irregular use of iron chelating 
agents were more likely to have higher cardiac iron load 
(P = 0.028), but not liver iron load (P = 0.110). The type of 
iron chelators used was not associated with liver or cardiac 
iron load (Table 3).
Significant variables from previous analyses were includ-
ed in the multiple regression analysis. The significant pre-
dictor of liver iron load was serum ferritin (R2 = 0.263, F(1, 
tAble 2. liver and heart iron load according to sex, and serum aspartate aminotransferase (ASt), alanine aminotransferase (Alt), and 
ferritin levels
no. (%) of patients with
liver iron load heart iron load
Parameter normal mild moderate severe P* normal mild moderate severe P*
Sex
male  6 (15.4) 15 (38.5) 17 (43.6) 1 (2.6) 0.032 31 (60.8) 12 (23.5) 4 (7.8) 4 (7.8) 0.966
female 17 (33.3) 21 (41.2) 10 (19.6) 3 (5.9) 24 (61.5)  8 (20.5) 3 (7.7) 4 (10.3)
Serum ASt
low 18 (25.4) 33 (46.5) 18 (25.4) 2 (2.8) 0.107 47 (66.2) 15 (21.1) 5 (7) 4 (5.6) 0.03
high  5 (26.3)  3 (15.8)  9 (47.4) 2 (10.5)  8 (42.1)  5 (26.3) 2 (10.5) 4 (21.1)
Serum Alt
low  0 (0) 34 (94.4)  2 (5.6) 0 (0) 0.48 22 (61.1)  8 (22.2) 3 (8.3) 3 (8.3) 0.989
high 23 (42.6)  2 (3.7) 25 (46.3) 4 (7.4) 33 (61.1) 12 (22.2) 4 (7.4) 5 (9.3)
Serum ferritin
low 20 (39.2) 19 (37.3) 11 (21.6) 1 (2) 0.001 39 (76.5)  7 (13.7) 2 (3.9) 3 (5.9) 0.001
high  3 (7.7) 17 (46.3) 16 (41) 3 (7.7) 16 (41) 13 (33.3) 5 (12.8) 5 (12.8)
*Fisher-exact test.
tAble 3. liver and heart iron load according to regularity and type of iron-chelating agent (iCA)
no. (%) of patients with
liver iron load heart iron load
Parameter normal mild moderate severe P* normal mild moderate severe P*
use of iCA
regular 19 (31.1) 23 (37.7) 17 (27.9) 2 (3.3) 0.110 41 (67.2) 14 (23) 4 (6.6) 2 (3.3) 0.028
irregular  4 (13.8) 13 (44.8) 10 (34.5) 2 (6.9) 14 (48.3)  6 (20.7) 3 (10.3) 6 (20.7)
type of iCA
deferoxamine (DFO) 11 (21.2) 20 (38.5) 18 (34.6) 3 (5.8) 0.222 30 (57.7)  9 (17.3) 6 (11.5) 7 (13.5) 0.092
deferasirox (DFX)  9 (30) 12 (40)  8 (26.7) 1 (3.3) 22 (73.3)  7 (23.3) 1 (3.3) 0 (0)
DFO and DFX  3 (37.5)  4 (50)  1 (12.5) 0 (0)  3 (37.5)  4 (50) 0 (0) 1 (12.5)
*Fisher-exact test.
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88) = 6.51, P = 0.012). When cardiac iron load was entered 
into a regression model with serum AST, serum ferritin, and 
regularity of use of iron chelators, only serum ferritin was 
able to add predictive value to the model estimate, with 
an R2 = 0.314 (F (3, 86) = 3.77) and P = 0.014.
diSCuSSion
This study for the first time showed that higher serum fer-
ritin strongly predicted the severity of hepatic and cardiac 
iron load. Irregular use of chelator drugs was associated 
with a higher risk of myocardial and liver iron load, regard-
less of the chelating agent type.
Over the last decade, life expectancy of patients with transfu-
sion-dependent TM has dramatically improved. Cardiac com-
plications, which can be divided into those caused by iron-
overload and those not caused by non-iron-overload, are 
crucial predictors of the quality of life and mortality in these 
patients (29). Liver iron overload is an important indicator of 
iron balance status in patients with TM. Its robust correlation 
with whole body iron has made it a valuable tool that can be 
used when tailoring the iron chelators treatment (30).
A major problem in studies focusing on the efficacy of iron 
chelation therapy is to accurately evaluate patients’ com-
pliance with DFO and DFX, which we calculated based 
on completed infusions and a self-report questionnaire, 
respectively. A combined treatment with DFO and DFX is 
more commonly prescribed in patients with high serum 
ferritin, AST, and/or ALT values at baseline, or as an urgent 
iron detoxification treatment when severe cardiovascu-
lar morbidities are present (31,32). Among our patients, 
those with the irregular use of iron chelating agents were 
more likely to have higher grades of iron load in cardiac tis-
sue, but not in the liver; while cardiac or hepatic iron load 
was not significantly associated with the type of chelating 
agent. Therefore, the dosage and regularity of iron chela-
tion had a greater impact on cardiovascular morbidity in 
these patients than the type of chelating drug.
LIC is the most accurate proxy of total body iron burden 
as more than 70% of total iron is stored in the liver (33). 
Moreover, hepatic siderosis correlates with iron overload in 
other organs. However the correlation with iron overload 
in the heart was observed with only in the cases of heavy 
iron deposition in the myocardium. This weak correlation 
might be explained by differences in iron kinetics, trans-
ferin receptor concentration, and the level of fibrosis or 
inflammation (34,35).
MRI-based organ assessment is now globally introduced 
as the gold standard for screening of liver and cardiac iron 
overload, replacing tissue biopsy and other invasive meth-
ods (36). The use of this method led to the improvement 
of both LIC and cardiac iron overload compared with the 
pre T2*MRI era (37). Nonetheless, Kolnagou et al (17) found 
that iron stores were not predicted by ferritin, but rather by 
chelation protocol, and genetic and dietary factors. This is 
in line with the findings that serum ferritin level was not a 
reliable predictor of liver iron load in patients with thalas-
semia intermedia under regular RBC transfusion (19).
We showed for the first time that ferritin can predict iron 
overload in the myocardium and liver tissues. Zamani et al 
(38) revealed no correlation between the histological grade 
of siderosis (HGS) and serum ferritin, but found a moderate 
correlation between serum ferritin levels and hepatic T2* 
levels. The correlation between ferritin and heart and liver 
T2*MRI values might be used as a proxy to estimate body 
iron levels.
Iron overload in patients with beta-TM is a direct result of 
transfusion, although it has also been associated with a few 
genetic loci (39). In patients with thalassemia intermedia, 
regardless of blood transfusion, the high risk of iron over-
load might be predicted by mutations in HFE gene (40).
The significance of total body iron status in tailoring chela-
tion therapy and the selection of the most appropriate 
management strategies is under-appreciated. Several sur-
veys have documented the impact of MRI availability on 
clinical outcomes of transfusion in patients with anemia 
(41,42). Also, appropriate iron chelation not only improves 
hematopoietic insufficiency in patients with myelodys-
plastic syndrome but also lowers the rate of progression 
toward leukemia, possibly by mitigating the mutagenic ef-
fect of iron free radicals (43).
Limitations of this study include a single assessment of 
AST, ALT, and serum ferritin based on laboratory data for 
each patient. Usually the average of the values obtained in 
the last 6 months is considered; however there are studies 
reporting a single measurement of serum ferritin values in 
relation with T2* MRI in beta- TM patients (18). Moreover, 
MRI iron measurements were read locally and were not 
centrally validated.
In conclusion, our results strongly support that iron and 
oral chelation in thalassemia patients should be assessed 
at least annually with T2*MRI. A consensus recommenda-
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tion of previous studies was to obtain the first T2*MRI at 
the age of 10, with more frequent imaging if T2* is less 
than 10-20 ms. In transfusion-dependent TM patients, it 
is also recommended to annually measure hepatic mark-
ers, although it was not specified starting from what age, 
with the aim of adjusting these markers to chelation (44). 
Nonetheless, the prevention of iron overload in TM re-
quires the clinicians’ cooperation with pathologists and 
biochemists. Future studies should investigate the ability 
of cost-effective serum markers to monitor iron overload 
in crucial organs.
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